JPH09257781A - Analysis of impurities of platinum compound - Google Patents
Analysis of impurities of platinum compoundInfo
- Publication number
- JPH09257781A JPH09257781A JP6755896A JP6755896A JPH09257781A JP H09257781 A JPH09257781 A JP H09257781A JP 6755896 A JP6755896 A JP 6755896A JP 6755896 A JP6755896 A JP 6755896A JP H09257781 A JPH09257781 A JP H09257781A
- Authority
- JP
- Japan
- Prior art keywords
- platinum
- trans
- cis
- cyclohexanediamine
- chemical formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、医薬品(制ガン
剤)の原薬となる1、2−シクロヘキサンジアミン異性
体のシス白金(II)錯体、特にシス−オキザラート(トラ
ンス−(−)−1、2−シクロヘキサンジアミン)白金
(II)中の不純物、1、2−シクロヘキサンジアミン異性
体のシス白金(IV)トランス−ジヒドロキソ錯体(以下ジ
ヒドロキソ体という)の分析方法に関する。TECHNICAL FIELD The present invention relates to a cis-platinum (II) complex of a 1,2-cyclohexanediamine isomer, which is a drug substance for a drug (anticancer drug), and particularly cis-oxalate (trans-(-)-1,2. -Cyclohexanediamine) platinum
The present invention relates to a method for analyzing impurities in (II), a cis-platinum (IV) trans-dihydroxo complex of 1,2-cyclohexanediamine isomer (hereinafter referred to as a dihydroxo body).
【0002】[0002]
【従来の技術】医薬品の原薬としては、含有するすべて
の不純物を特定する必要があり、特に毒性や制ガン活性
を持つ不純物は検出定量が重要となる。従来の含有成分
分析方法の1つとしてODSカラムを用いた高速液体ク
ロマトグラフィ(HPLC)法があったが、種々の条件
設定により各々特徴を有することを見いだし、その知見
に基づいて従来特に分離検出できなかった不純物を特定
することに着目し、本発明に至った。2. Description of the Related Art It is necessary to identify all impurities contained in a drug substance of a drug, and it is particularly important to detect and quantify impurities having toxicity and anticancer activity. As one of the conventional methods for analyzing contained components, there was a high performance liquid chromatography (HPLC) method using an ODS column. However, it was found that each method has its own characteristics by setting various conditions, and based on this finding, it has been possible to separate and detect conventional methods. The present invention has been made paying attention to the identification of impurities that were not present.
【0003】[0003]
【発明が解決しようとする課題】本発明は、1、2−シ
クロヘキサンジアミン異性体のシス白金(II)錯体、特に
シス−オキザラート(トランス−(−)−1、2−シク
ロヘキサンジアミン)白金(II)中の不純物の分離定量す
る方法を提供することを目的とする。The present invention is directed to cis-platinum (II) complexes of 1,2-cyclohexanediamine isomers, especially cis-oxalate (trans-(-)-1,2-cyclohexanediamine) platinum (II). It is intended to provide a method for separating and quantifying impurities in).
【0004】[0004]
【課題を解決するための手段】本発明は、前記化1〜化
7で示される1、2−シクロヘキサンジアミン異性体の
シス白金(II)錯体の分離定量において、前記ジヒドロキ
ソ体を不純物として特定し、高速液体クロマトグラフィ
(HPLC)法にて分離定量することを特徴とするもの
で、特に、シス−オキザラート(トランス−(−)−
1、2−シクロヘキサンジアミン)白金(II)(l−OH
P)において顕著である。According to the present invention, the dihydroxo form is specified as an impurity in the separation and quantification of the cis-platinum (II) complex of the 1,2-cyclohexanediamine isomer represented by the chemical formulas 1 to 7. , High-performance liquid chromatography (HPLC) method for separation and quantification, and particularly cis-oxalate (trans-(-)-
1,2-cyclohexanediamine) platinum (II) (l-OH
It is remarkable in P).
【0005】また、本発明は、上記高速液体クロマトグ
ラフィ(HPLC)法において、ODSカラムを長さ20
cm〜50cmとすることを特徴とするもので、長さ20cm未満
では、ジヒドロキソ体の分離に不十分で、長さ50cmを超
えても分離効果にあまり変わりはみられず、作業性、効
率の点から前記範囲とした。Further, according to the present invention, in the above high performance liquid chromatography (HPLC) method, an ODS column having a length of 20 is used.
The length is less than 20 cm, the separation of the dihydroxo body is insufficient, and the separation effect does not change much even if the length exceeds 50 cm, and the workability and efficiency are improved. The above range was defined from the point.
【0006】また、設定条件として移動相を水、アセト
ニトリル又は緩衝液のいずれか1種又は2種の混液とす
るもので、特に水を用いることが効率的である。[0006] Further, as a set condition, the mobile phase is water, acetonitrile, or a mixed solution of any one or two kinds of buffer solutions, and it is particularly efficient to use water.
【0007】さらに溶離液の流量としては 0.1〜5ml/m
inが好ましく、1ml/minがより好ましい。Further, the flow rate of the eluent is 0.1-5 ml / m
In is preferable, and 1 ml / min is more preferable.
【0008】[0008]
【発明の実施の形態】本発明においては、ODSカラム
は担持されるオクタデシル基をもつ化合物他によって分
離が異なり、その為、適切なODSカラムの設定や適切
な溶離液や条件の設定によって、初めてヒジドロキソ体
の分離が可能となったものである。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the separation of the ODS column differs depending on the compound having an octadecyl group and the like, and therefore, the ODS column cannot be separated by setting an appropriate ODS column or setting an appropriate eluent and conditions. It is now possible to separate the body of Hijidroxo.
【0009】[0009]
【実施例】以下に実施例と従来例について述べる。本発
明に係わる化1のなかで化2のl−OHPにおける不純
物の分離定量を行った。絶対検量法に従って行い、不純
物として考えられる成分のスタンダードの既知量を段階
的に導入し、そのクロマトグラフのピーク面積を測定
し、成分量を横軸に、ピーク面積を縦軸にプロットして
検量線を作成した。EXAMPLES Examples and conventional examples will be described below. In Chemical Formula 1 according to the present invention, separation and quantification of impurities in 1-OHP of Chemical formula 2 were performed. Perform according to the absolute calibration method, introduce stepwise a known amount of the standard of the component considered as an impurity, measure the peak area of the chromatograph, plot the component amount on the horizontal axis, and plot the peak area on the vertical axis for calibration. Created a line.
【0010】次に、l−OHPをHPLCにて測定し、
ピーク面積から検量線にて披検成分の量を求め、試料中
の含有率を算出した。その結果を表1に示す。Next, l-OHP was measured by HPLC,
The amount of the test component was determined from the peak area by a calibration curve, and the content rate in the sample was calculated. Table 1 shows the results.
【0011】[0011]
【表1】 [Table 1]
【0012】その際、クロマトグラフの操作条件として
以下のように行った。実施例として、 カラム:内径約 4.6mm、長さ25cmのステンレス管にオク
タデシルシリル化シリカゲルを充填したもの(ハイパー
シル:ジーエルサイエンス社製商品名) カラム温度:室温 移動相:水 流 量:1ml/min 検出器:uv− 210nm(紫外線吸光光度計) 注入量:20μl 試料:l−OHP標準液を40mg/ 100ml、ジヒドロキソ
体を1mg/ 100ml(サンプル量:20mg/ 100ml) の条件にて行った。At that time, the operating conditions of the chromatograph were as follows. As an example, a column: a stainless tube having an inner diameter of about 4.6 mm and a length of 25 cm packed with octadecylsilylated silica gel (Hypersil: trade name of GL Sciences Inc.) Column temperature: room temperature Mobile phase: water flow rate: 1 ml / min Detector: uv-210 nm (ultraviolet absorptiometer) Injection amount: 20 μl Sample: l-OHP standard solution was 40 mg / 100 ml, and dihydroxo was 1 mg / 100 ml (sample amount: 20 mg / 100 ml).
【0013】一方、従来例として カラム:内径約 4.6mm、長さ15cmのステンレス管にオク
タデシルシリル化シカゲルを充填したもの(コスモシ
ル:ナカライテスク社製商品名) カラム温度40℃ 移動相:メタノールと水の混合比(6:4)の溶媒、 流 量: 0.7ml/min 検出器:uv− 220nm(紫外線吸光光度計) とした他は実施例と同じにした。On the other hand, as a conventional example, a column: a stainless tube having an inner diameter of about 4.6 mm and a length of 15 cm filled with octadecylsilylated shikagel (Cosmosil: trade name of Nacalai Tesque, Inc.) Column temperature 40 ° C. Mobile phase: methanol and water The solvent was used in the same mixing ratio (6: 4), the flow rate was 0.7 ml / min, and the detector was uv-220 nm (ultraviolet absorptiometer).
【0014】上記の結果から明らかなように、従来例に
おいては分離定量できなかったジヒドロキソ体含量が実
施例においては「0.12%」と分離定量できた。As is clear from the above results, the content of dihydroxo form which could not be separated and quantified in the conventional example was "0.12%" in the example and could be quantified.
【0015】[0015]
【発明の効果】以上説明したように、本発明の白金化合
物の不純物分析方法により、1、2−シクロヘキサンジ
アミン異性体のシス白金(II)錯体、特にシス−オキザラ
ート(トランス−(−)−1、2−シクロヘキサンジア
ミン)白金(II)中の不純物の分離定量が可能となり、医
薬品(制ガン剤)の原薬の適正な評価、管理、運用に寄
与するところ大である。As described above, according to the method for analyzing impurities of the platinum compound of the present invention, the cis-platinum (II) complex of 1,2-cyclohexanediamine isomer, especially cis-oxalate (trans-(-)-1) is used. , 2-Cyclohexanediamine) platinum (II) can be separated and quantified, which contributes to the proper evaluation, management, and operation of the drug substance of a drug (anticancer drug).
Claims (5)
は、シス、トランス−d又はトランス−l体であり、R
1 、R2 はPt(II)と環状となって化2、化3、化4、
化5、化6又は化7となるもの) 【化2】 【化3】 【化4】 【化5】 【化6】 【化7】 で示される1、2−シクロヘキサンジアミン異性体のシ
ス白金(II)錯体の分離定量において、 【化8】 (式中、1、2−シクロヘキサンジアミンの立体配位
は、シス、トランス−d又はトランス−l体であり、R
1 、R2 はPt(IV)と環状になって化2、化3、化4、
化5、化6又は化7となるもの)で示される1、2−シ
クロヘキサンジアミン異性体のシス白金(IV)トランス−
ジヒドロキソ錯体(以下ジヒドロキソ体)を不純物とし
て高速液体クロマトグラフィ(HPLC)法にて分離定
量することを特徴とする白金化合物の不純物分析方法。[Claim 1] (Wherein the steric configuration of 1,2-cyclohexanediamine is cis, trans-d or trans-1 isomer;
1 , R 2 becomes a ring with Pt (II) to form 2, 3, and 4,
Chemical formula 5, Chemical formula 6 or Chemical formula 7) Embedded image Embedded image Embedded image [Chemical 6] Embedded image In the separation and quantification of cis-platinum (II) complex of 1,2-cyclohexanediamine isomer represented by (Wherein the steric configuration of 1,2-cyclohexanediamine is cis, trans-d or trans-1 isomer;
1 , R 2 becomes a ring with Pt (IV) to form
Chemical formula 5, chemical formula 6 or chemical formula 7), a cis-platinum (IV) trans-form of the 1,2-cyclohexanediamine isomer
A method for analyzing impurities in a platinum compound, which comprises separating and quantifying a dihydroxo complex (hereinafter referred to as a dihydroxo form) as an impurity by a high performance liquid chromatography (HPLC) method.
のシス白金(II)錯体において、シス−オキザラート(ト
ランス−(−)−1、2−シクロヘキサンジアミン)白
金(II)(l−OHP)とする請求項1記載の白金化合物
の不純物分析方法。2. A cis-platinum (II) complex of a 1,2-cyclohexanediamine isomer is cis-oxalate (trans-(-)-1,2-cyclohexanediamine) platinum (II) (1-OHP). The method for analyzing impurities of a platinum compound according to claim 1.
法におけるODSカラムを長さ20cm〜50cmとする請求項
1及び請求項2記載の白金化合物の不純物分析方法。3. High performance liquid chromatography (HPLC)
The method for analyzing impurities of a platinum compound according to claim 1 or 2, wherein the ODS column in the method has a length of 20 cm to 50 cm.
法において、移動相を水、アセトニトリル又は緩衝液の
いずれか1種又は2種の混液とする請求項1、請求項2
及び請求項3記載の白金化合物の不純物分析方法。4. High performance liquid chromatography (HPLC)
In the method, the mobile phase is water, acetonitrile, or a mixed solution of any one or two kinds of buffer solutions.
And a method for analyzing impurities in a platinum compound according to claim 3.
おいて、溶離液の流量を 0.1〜5ml/minとする請求項
1、請求項2、請求項3及び請求項4記載の白金化合物
の不純物分析方法。5. The method for analyzing impurities of platinum compounds according to claim 1, claim 2, claim 3 or claim 4, wherein the flow rate of the eluent is 0.1 to 5 ml / min in the high performance chromatography (HPLC) method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP08067558A JP3118184B2 (en) | 1996-03-25 | 1996-03-25 | Platinum compound impurity analysis method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP08067558A JP3118184B2 (en) | 1996-03-25 | 1996-03-25 | Platinum compound impurity analysis method |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09257781A true JPH09257781A (en) | 1997-10-03 |
JP3118184B2 JP3118184B2 (en) | 2000-12-18 |
Family
ID=13348423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP08067558A Expired - Fee Related JP3118184B2 (en) | 1996-03-25 | 1996-03-25 | Platinum compound impurity analysis method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3118184B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109580822A (en) * | 2018-12-21 | 2019-04-05 | 山东铂源药业有限公司 | Left-handed-anti-form-1, the detection method of the cis- -1,2- cyclohexanediamine of impurity in 2- cyclohexanediamine |
CN110596282A (en) * | 2018-06-13 | 2019-12-20 | 上海医药工业研究院 | Nedaplatin compound, separation method and application |
CN111175423A (en) * | 2016-12-23 | 2020-05-19 | 江苏奥赛康药业有限公司 | Method for analyzing nedaplatin |
-
1996
- 1996-03-25 JP JP08067558A patent/JP3118184B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111175423A (en) * | 2016-12-23 | 2020-05-19 | 江苏奥赛康药业有限公司 | Method for analyzing nedaplatin |
CN110596282A (en) * | 2018-06-13 | 2019-12-20 | 上海医药工业研究院 | Nedaplatin compound, separation method and application |
CN109580822A (en) * | 2018-12-21 | 2019-04-05 | 山东铂源药业有限公司 | Left-handed-anti-form-1, the detection method of the cis- -1,2- cyclohexanediamine of impurity in 2- cyclohexanediamine |
CN109580822B (en) * | 2018-12-21 | 2021-03-19 | 山东铂源药业有限公司 | Method for detecting cis-1, 2-cyclohexanediamine impurity in levo-trans-1, 2-cyclohexanediamine |
Also Published As
Publication number | Publication date |
---|---|
JP3118184B2 (en) | 2000-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chaves et al. | Microextraction in packed sorbent for analysis of antidepressants in human plasma by liquid chromatography and spectrophotometric detection | |
Ferdig et al. | Improved capillary electrophoretic separation of nine (fluoro) quinolones with fluorescence detection for biological and environmental samples | |
Needham et al. | Optimized stationary phases for the high-performance liquid chromatography–electrospray ionization mass spectrometric analysis of basic pharmaceuticals | |
D’Orazio et al. | Nano-liquid chromatography coupled with mass spectrometry: Separation of sulfonamides employing non-porous core–shell particles | |
Pena et al. | Determination of tetracycline and its major degradation products by liquid chromatography with fluorescence detection | |
Yoshida et al. | Highly selective and sensitive determination of tricyclic antidepressants in human plasma using high-performance liquid chromatography with post-column tris (2, 2′-bipyridyl) ruthenium (III) chemiluminescence detection | |
Dahane et al. | Mesoporous silica based MCM-41 as solid-phase extraction sorbent combined with micro-liquid chromatography–quadrupole-mass spectrometry for the analysis of pharmaceuticals in waters | |
Miguel et al. | LC determination of impurities in azithromycin tablets | |
Geisslinger et al. | Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma | |
juan Song et al. | Microemulsion liquid chromatographic method for simultaneous separation and determination of six flavonoids of Apocynum venetum leaf extract | |
Pittler et al. | Enantioseparation of dansyl amino acids by HPLC on a monolithic column dynamically coated with a vancomycin derivative | |
CN107167535B (en) | Method for detecting raltitrexed enantiomer by reversed phase liquid chromatography | |
JP3118184B2 (en) | Platinum compound impurity analysis method | |
CN116699038A (en) | Detection and analysis method for related substances in lidocaine gel plaster | |
Ye et al. | Vitamin E content of margarine and reduced fat products using a simplified extraction procedure and HPLC determination | |
Papadoyannis et al. | A rapid high performance liquid chromatographic (HPLC) assay for the determination of oxytetracycline in commercial pharmaceuticals | |
Van de Merbel et al. | Experiences with monolithic LC phases in quantitative bioanalysis | |
Van Schoors et al. | Miniaturized ultra-high performance liquid chromatography coupled to electrochemical detection: Investigation of system performance for neurochemical analysis | |
Vasudevan et al. | Simultaneous estimation of phenylpropanolamine HCl, guaiphenesin and diphenylpyraline HCl in syrups by LC | |
CN110702803A (en) | Detection method of vildagliptin enantiomer | |
Ulrich | Sensitive gas-liquid chromatographic method for the assay of the neuroleptic drug cis (Z)-flupentixol in human serum or plasma | |
Williams et al. | A rapid method for the determination of therapeutic barbiturate levels in serum using gas-liquid chromatography | |
Van de Merbel et al. | Determination of pilocarpine, isopilocarpine, pilocarpic acid and isopilocarpic acid in human plasma and urine by high-performance liquid chromatography with tandem mass spectrometric detection | |
CN109738536B (en) | Method for separating benzaldehyde and nitrobenzaldehyde by using high performance liquid chromatography | |
Lefebvre et al. | Simultaneous determination of all-trans and 13-cis retinoic acids and their 4-oxo metabolites by adsorption liquid chromatography after solid-phase extraction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |